Transitioning between therapeutic anticoagulants: a clinicians guide to switching patients to or from DOAC therapy
Authors:
- 2 October 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 22 (10) , 589-602
Abstract
IntroductionThe transition to or from direct oral anticoagulants (DOACs) is common in clinical practice.Areas coveredA literature search was conducted on PubMed, Google Scholar, and UpToDate up to March 2024 for conditions and approaches for transitioning from one agent to the other. No randomized clinical trials were retrieved except for two studies regarding switching to DOAC in well-conducted vitamin K antagonist (VKA) therapy. A narrative review was conducted addressing the conditions for switching from one agent to the other, such as thromboembolic events and major bleeding during anticoagulation, development or worsening of kidney or liver failure, initiation of interfering drugs, adverse events such as allergic reactions, frailty, patients' preferences, and affordability. During transitions from one anticoagulant to the other, the risk of both thromboembolic and bleeding complications should be minimized. The current approaches for such transitions are derived from those employed in clinical trials evaluating DOAC and from product information.Expert opinionMany uncertainties remain regarding those circumstances requiring a change in anticoagulant strategies, as they lack evidence-based guidance. It can be envisaged that the problem of switching to and from DOAC will need additional studies especially addressing the conditions and the best approach to such transitions.Keywords
This publication has 78 references indexed in Scilit:
- Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety dataEuropean Journal of Clinical Pharmacology, 2024
- Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trialsJournal of Thrombosis and Thrombolysis, 2024
- Initial report of percutaneous left atrial appendage closure in hemodialysis patients with atrial fibrillation and high risk of bleeding in JapanCardiovascular Intervention and Therapeutics, 2022
- Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline RecommendationsJAMA Network Open, 2022
- Switching between direct oral anticoagulants: a systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2021
- Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulantsResearch and Practice in Thrombosis and Haemostasis, 2020
- Outcomes in a Warfarin-Treated Population With Atrial FibrillationJAMA Cardiology, 2016
- Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentJournal of Thrombosis and Thrombolysis, 2016
- Pharmacology of the new target-specific oral anticoagulantsJournal of Thrombosis and Thrombolysis, 2013
- The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral HemorrhageArchives of internal medicine (1960), 2004